Do no do examples

Do no do examples for Cardiovascular disease: risk assessment and reduction, including lipid modification
Title Year published Impact Level
Do not use a risk assessment tool to assess CVD risk in people with an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2 and/or albuminuria. These people are at increased risk of CVD. December 2016 Unclassified
A fasting sample is not required when taking samples before starting lipid modification therapy for the primary prevention of CVD. Take at least 1 lipid sample to measure a full lipid profile. December 2016 Unclassified
Do not use opportunistic assessment as the main strategy in primary care to identify CVD risk in unselected people. December 2016 Unclassified
Do not use a risk assessment tool to assess CVD risk in people with type 1 diabetes. December 2016 Unclassified
Do not use a risk assessment tool for CVD, for people with pre-existing CVD. December 2016 Unclassified
Do not use a risk assessment tool for people who are at high risk of developing CVD because of familial hypercholesterolaemia. December 2016 Unclassified
Do not advise any of the following to take plant stanols or sterols for the prevention of CVD: people who are being treated for primary prevention, people who are being treated for secondary prevention, people with CKD, people with type 1 diabetes, people with type 2 diabetes. December 2016 Unclassified
Do not delay statin treatment in secondary prevention to manage modifiable risk factors. December 2016 Unclassified
Do not delay statin treatment if a person has acute coronary syndrome. Take a lipid sample on admission and about 3 months after the start of treatment. December 2016 Unclassified
Do not start statin treatment if creatine kinase levels are more than 5 times the upper limit of normal, in 2 tests 7 days apart. Perform these tests when considering starting statin treatment for people who have had persistent generalised unexplained muscle pain (with or without lipid-loewring therapy). December 2016 Unclassified
Do not measure creatine kinase levels in asymptomatic people who are being treated with a statin. December 2016 Unclassified
Do not routinely exclude from statin therapy people who have liver transaminase levels that are raised but are less than 3 times the upper limit of normal. December 2016 Unclassified
Do not stop statins because of an increase in blood glucose level or HbA1c December 2016 Unclassified
Do not offer coenzyme Q10 or vitamin D to increase adherence to statin treatment. December 2016 Unclassified
Do not offer a bile acid sequestrant (anion exchange resin) for the prevention of CVD to any of the following: people who are being treated for primary prevention, people who are being treated for secondary prevention, people with CKD, people with type 1 diabetes, people with type 2 diabetes. December 2016 Unclassified
Do not offer omega-3 fatty acid compounds for the prevention of CVD to any of the following: people who are being treated for primary prevention, people who are being treated for secondary prevention, people with CKD, people with type 1 diabetes, people with type 2 diabetes. December 2016 Unclassified
Do not offer the combination of a bile acid sequestrant (anion exchange resin), fibrate, nicotinic acid or omega-3 fatty acid compound with a statin for the primary or secondary prevention of CVD. December 2016 Unclassified
Do not offer nicotinic acid (niacin) for the prevention of CVD to any of the following: people who are being treated for primary prevention, people who are being treated for secondary prevention, people with CKD, people with type 1 diabetes, people with type 2 diabetes. December 2016 Unclassified
Do not routinely offer fibrates for the prevention of CVD to any of the following: people who are being treated for primary prevention, people who are being treated for secondary prevention, people with CKD, people with type 1 diabetes, people with type 2 diabetes. December 2016 Unclassified
Do not use a risk assessment tool to assess CVD risk in people with type 1 diabetes. July 2014 Unclassified
Do not use a risk assessment tool to assess cardiovascular disease (CVD) risk in people with an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2 and/or albuminuria[4]. These people are at increased risk of CVD. July 2014 Unclassified
Do not use a risk assessment tool for people with pre-existing cardiovascular disease (CVD). July 2014 Unclassified
Do not advise any of the following to take plant stanols or sterols for the prevention of CVD: -people who are being treated for primary prevention -people who are being treated for secondary prevention -people with CKD -people with type 1 diabetes -people with type 2 diabetes July 2014 Unclassified
Do not measure creatine kinase levels in asymptomatic people who are being treated with a statin. July 2014 Unclassified
Do not stop statins because of an increase in blood glucose level or HbA1c. July 2014 Unclassified
Do not offer coenzyme Q10 or vitamin D to increase adherence to statin treatment. July 2014 Unclassified
Do not routinely offer fibrates for the prevention of CVD to any of the following: -people who are being treated for primary prevention -people who are being treated for secondary prevention -people with CKD -people with type 1 diabetes -people with type 2 diabetes. July 2014 Unclassified
Do not offer nicotinic acid (niacin) for the prevention of CVD to any of the following: people who are being treated for primary prevention people who are being treated for secondary prevention people with CKD people with type 1 diabetes people with type 2 diabetes July 2014 Unclassified
Do not offer omega-3 fatty acid compounds for the prevention of CVD to any of the following: people who are being treated for primary prevention people who are being treated for secondary prevention people with CKD people with type 1 diabetes people with type 2 diabetes. [new 2014] July 2014 Unclassified
Do not offer the combination of a bile acid sequestrant (anion exchange resin), fibrate, nicotinic acid or omega-3 fatty acid compound with a statin for the primary or secondary prevention of CVD. July 2014 Unclassified
Do not offer a bile acid sequestrant (anion exchange resin) for the prevention of CVD to any of the following: people who are being treated for primary prevention people who are being treated for secondary prevention people with CKD people with type 1 diabetes people with type 2 diabetes July 2014 Unclassified